Suresh Shelat MD, PhD
About Suresh Shelat MD, PhD
Suresh Shelat MD, PhD, is the Senior Director of Immuno-Oncology Cellular Therapy Clinical Development at Bristol Myers Squibb. He has extensive experience in clinical trial management, regulatory filings, and leveraging digital health technologies to improve diagnostics and disease monitoring.
Title
Suresh Shelat, MD, PhD, holds the position of Senior Director in Immuno-Oncology Cellular Therapy Clinical Development at Bristol Myers Squibb.
Professional Experience
Suresh Shelat has an extensive background in the pharmaceutical and healthcare sectors. He is currently serving as the Senior Director in Immuno-Oncology Cellular Therapy Clinical Development at Bristol Myers Squibb. Previously, he served as the Director of Clinical Experimental Pharmacology at Sanofi from 2013 to 2014. Additionally, he has held roles at Penn Medicine, University of Pennsylvania Health System, as an Assistant Professor from 2003 to 2010, and at the Children's Hospital of Philadelphia as Medical Director, Hematology/Oncology Laboratory and Attending Physician during the same period.
Education and Expertise
Suresh Shelat holds an MD and PhD from the University of Pennsylvania School of Medicine and a B.Sc from the Massachusetts Institute of Technology. Additionally, he has pursued studies in Business at the University of Pennsylvania's Wharton School and in Clinical Epidemiology & Biostatistics at the University of Pennsylvania School of Medicine. His expertise spans across clinical oncology, hematology, and pharmacology, with specialization in hematology/oncology Phase I-III clinical trials and innovative approaches to clinical trial execution.
Clinical Trials and Research
Suresh Shelat has contributed significantly to clinical trials, including serving as the clinical lead for the idecabtagene vicleucel (Abecma) trial in multiple myeloma. His work has focused on optimizing autologous CAR-T and off-the-shelf allogeneic cellular therapies. He has successfully contributed to s/BLA and sNDA registrational filings in multiple myeloma and leukemia and led the ELOQUENT-3 study, which resulted in sBLA approval and publication in the New England Journal of Medicine. His experience includes managing CRO, IRC, DMC processes, and authoring essential regulatory documents.
Innovations and Leadership
Suresh Shelat has developed innovative approaches to enhance the efficiency of clinical trials. He has played a key role in navigating clinical holds and CAPAs, particularly during the COVID-19 pandemic. Additionally, he has harnessed digital health and AI/ML to improve diagnostics and disease monitoring in clinical trials. His business and management training has allowed him to create tools that expand organizational capabilities and produce decision-enabling data. He is also experienced in presenting complex scientific and clinical concepts to diverse audiences.